Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P47985

UPID:
UCRI_HUMAN

ALTERNATIVE NAMES:
Complex III subunit 5; Cytochrome b-c1 complex subunit 5; Rieske iron-sulfur protein; Rieske protein UQCRFS1; Ubiquinol-cytochrome c reductase iron-sulfur subunit

ALTERNATIVE UPACC:
P47985; A8K519; Q6NVX5; Q9UPH2

BACKGROUND:
UQCRFS1, or the Rieske iron-sulfur protein, is integral to the mitochondrial electron transport chain, specifically within the cytochrome b-c1 complex. It is crucial for the Q cycle, a process that generates an electrochemical gradient used to produce ATP. The protein's function underscores the complex interplay of components necessary for cellular respiration.

THERAPEUTIC SIGNIFICANCE:
The association of UQCRFS1 with Mitochondrial complex III deficiency, nuclear type 10, underscores its therapeutic significance. This genetic disorder's diverse manifestations, from alopecia totalis to cardiomyopathy, emphasize the need for targeted therapies. Exploring UQCRFS1's role could lead to breakthroughs in treating mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.